BR112017027304A2 - método para o diagnóstico de doença de farber - Google Patents
método para o diagnóstico de doença de farberInfo
- Publication number
- BR112017027304A2 BR112017027304A2 BR112017027304A BR112017027304A BR112017027304A2 BR 112017027304 A2 BR112017027304 A2 BR 112017027304A2 BR 112017027304 A BR112017027304 A BR 112017027304A BR 112017027304 A BR112017027304 A BR 112017027304A BR 112017027304 A2 BR112017027304 A2 BR 112017027304A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- farber
- diagnosis
- individual
- ceramide
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
a presente invenção está relacionada a um método para o diagnóstico da doença de farber em um indivíduo, em que o método compreende a detecção de c26 ceramida em uma amostra do indivíduo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15002041.0A EP3115786A1 (en) | 2015-07-08 | 2015-07-08 | Method for the diagnosis of farber's disease |
PCT/EP2016/001182 WO2017005374A1 (en) | 2015-07-08 | 2016-07-08 | Method for the diagnosis of farber's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017027304A2 true BR112017027304A2 (pt) | 2018-09-04 |
Family
ID=53673711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017027304A BR112017027304A2 (pt) | 2015-07-08 | 2016-07-08 | método para o diagnóstico de doença de farber |
Country Status (8)
Country | Link |
---|---|
US (1) | US11204357B2 (pt) |
EP (2) | EP3115786A1 (pt) |
CN (1) | CN109348728A (pt) |
AU (1) | AU2016290904A1 (pt) |
BR (1) | BR112017027304A2 (pt) |
CA (1) | CA2991345A1 (pt) |
MX (1) | MX2018000189A (pt) |
WO (1) | WO2017005374A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020008377A (es) * | 2018-03-27 | 2020-09-25 | Enzyvant Therapeutics Gmbh | Marcadores de la enfermedad de farber y usos de estos. |
GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
WO2023232942A1 (en) * | 2022-06-01 | 2023-12-07 | Universiteit Antwerpen | Method for detecting lysosomal storage disease biomarkers and kits for performing the method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100233680A1 (en) * | 2005-11-12 | 2010-09-16 | Siemens Healthcare Diagnostics Inc. | Gene Expression Profiles and Methods of Use |
-
2015
- 2015-07-08 EP EP15002041.0A patent/EP3115786A1/en not_active Ceased
-
2016
- 2016-07-08 AU AU2016290904A patent/AU2016290904A1/en not_active Abandoned
- 2016-07-08 CN CN201680039756.4A patent/CN109348728A/zh active Pending
- 2016-07-08 MX MX2018000189A patent/MX2018000189A/es unknown
- 2016-07-08 EP EP16744301.9A patent/EP3320344A1/en not_active Ceased
- 2016-07-08 CA CA2991345A patent/CA2991345A1/en not_active Abandoned
- 2016-07-08 US US15/742,317 patent/US11204357B2/en active Active
- 2016-07-08 BR BR112017027304A patent/BR112017027304A2/pt not_active IP Right Cessation
- 2016-07-08 WO PCT/EP2016/001182 patent/WO2017005374A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN109348728A (zh) | 2019-02-15 |
AU2016290904A1 (en) | 2018-01-04 |
MX2018000189A (es) | 2018-08-01 |
CA2991345A1 (en) | 2017-01-12 |
US11204357B2 (en) | 2021-12-21 |
US20180203024A1 (en) | 2018-07-19 |
WO2017005374A1 (en) | 2017-01-12 |
EP3320344A1 (en) | 2018-05-16 |
EP3115786A1 (en) | 2017-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016010975A2 (pt) | método e aparelho para identificar um dispositivo de iot físico | |
BR112018010211A2 (pt) | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab | |
BR112017023872A2 (pt) | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos | |
BR112016024494A2 (pt) | análogos de peptídeo com sonda(s) de aminoácidos ramificados | |
BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
BR112015032507A2 (pt) | método para derivar pontuação de fadiga, dispositivo de detecção de sonolência e elemento de programa de computador | |
BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
BR112015025407A2 (pt) | método e dispositivo para testar um transformador | |
BR112014009223A8 (pt) | método para o diagnóstico da doença de niemann-pick | |
BR112017025995A2 (pt) | inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal | |
BR112015019278A2 (pt) | processo de elastografia multi-impulsional | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
BR102012002812A8 (pt) | método para determinar a influência de uma variável em um fenômeno | |
WO2015034886A3 (en) | Wellness panel for companion animals | |
BR112016002668A2 (pt) | métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares | |
EP3285071A4 (en) | Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method | |
EA201591742A1 (ru) | Способ улучшения диагностики заболеваний с использованием измеряемых аналитов | |
BR112014026568A2 (pt) | método e aparelho para projeto de componentes de oleoduto | |
BR112018006018A2 (pt) | detecção de beta-amiloide através de espectrometria de massa | |
BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
BR112016019588A2 (pt) | produto de ativação de mmp-8, e, método de determinação da ativação da mmp-8 em uma amostra | |
WO2018199530A3 (ko) | 대사체 분석을 이용한 베체트병의 진단방법 | |
BR112019024661A2 (pt) | Isolamento de células de origem epitelial circulantes no sangue periférico | |
BR112017027304A2 (pt) | método para o diagnóstico de doença de farber |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: CENTOGENE AG (DE) |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: CENTOGENE GMBH (DE) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2730 DE 02-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |